Introduction
Introduction Statistics Contact Development Disclaimer Help
Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
Return to: AUBAGIO (teriflunomide)
*****************************************************
#Post#: 1828--------------------------------------------------
(Abst.) Aubagio in treatment of relapsing forms of MS...
By: agate Date: September 23, 2017, 8:24 pm
---------------------------------------------------------
From Therapeutic Advances in Neurological Disorders, September
21, 2017:
[quote]Oral teriflunomide in the treatment of relapsing forms of
multiple sclerosis: clinical evidence and long-term experience
Aaron E. Miller (Icahn School of Medicine at Mount Sinai,
Corinne Goldsmith Dickinson Center for Multiple Sclerosis)
Key objectives in the treatment of multiple sclerosis (MS)
include prevention of relapses, a reduction in the accumulation
of disability and slowing of the brain volume loss that occurs
from the earliest stages of the disease.
Teriflunomide, a once-daily, oral immunomodulatory therapy, has
demonstrated efficacy across multiple measures of disease
activity and worsening in patients with relapsing forms of MS
and in those with a first clinical episode suggestive of MS.
In this review, the latest evidence relating to the proposed
mechanism of action of teriflunomide in MS is explored,
including novel insights provided from the recently completed
Teri-DYNAMIC study. Key clinical and magnetic resonance imaging
data from the completed long-term extensions of the phase II and
III (TEMSO, TOWER and TOPIC) studies are highlighted, and the
long-term safety profile of teriflunomide, as evidenced by data
from these extension studies, is presented.
Although randomized clinical trials represent the highest level
of evidence to support the use of therapeutic interventions, it
is also important to understand the performance of a particular
treatment in the real-world setting. In this regard, the results
of the recently completed, global, phase IV Teri-PRO study are
of particular interest and provide further insights into the
benefits of teriflunomide treatment from the patient
perspective.
Collectively, the data presented in this review demonstrate a
favorable benefit�risk profile for teriflunomide, thereby
supporting its long-term use for the treatment of patients with
relapsing forms of MS.[/quote]
The abstract can be seen here
http://journals.sagepub.com/doi/abs/10.1177/1756285617722500.
*****************************************************
You are viewing proxied material from gopher.createaforum.com. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.